Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease

Autor: Blijdorp, C.J., Severs, D., Musterd-Bhaggoe, U.M., Gansevoort, R.T., Drenth, J.P.H., Wetzels, J.F.M., Zietse, R., Hoorn, E.J.

Publikováno v: Nephrology Dialysis Transplantation, 36(12), 2248-2255. Oxford University Press
Nephrology, Dialysis, Transplantation, 36, 12, pp. 2248-2255
Nephrology, Dialysis, Transplantation, 36(12). Oxford University Press
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation, 36(12), 2248-2255. OXFORD UNIV PRESS
Nephrology, Dialysis, Transplantation, 36, 2248-2255

Background Metabolic acidosis accelerates progression of chronic kidney disease, but whether this is also true for autosomal dominant polycystic kidney disease (ADPKD) is unknown. Methods Patients with ADPKD from the DIPAK (Developing Interventions t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc17df280601081bdd8c1befd96fa84
https://pure.eur.nl/en/publications/a53bb91b-72ea-4fcd-b145-aaee9bc2c9c7

Somatostatin in renal physiology and autosomal dominant polycystic kidney disease

Autor: Messchendorp, A.L., Casteleijn, N.F., Meijer, E., Gansevoort, R.T., Drenth, J.P., Fijter, J.W. de, Peters, D.J.M., Visser, F.W., Wetzels, J.F., Zietse, R., DIPAK Consortium Investigators

Publikováno v: Nephrology Dialysis Transplantation, 35(8), 1306-1316. OXFORD UNIV PRESS
Nephrology Dialysis Transplantation, 35(8), 1306-1316. Oxford University Press
Nephrology Dialysis Transplantation

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation, leading to growth in kidney volume and renal function decline. Although therapies have emerged, there is still an important unmet need for slowing th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::263b0962fed274fb56c0fd41782a9362
https://hdl.handle.net/1887/3184594

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease

Autor: Meijer, E., Visser, F.W., Aerts, R.M.M. van, Blijdorp, C.J., Casteleijn, N.F., D'Agnolo, H.M.A., Dekker, S.E.I., Drenth, J.P.H., Fijter, J. de, Gastel, M.D.A. van, Gevers, T.J., Lantinga, M.A., Losekoot, M., Messchendorp, A.L., Neijenhuis, M.K., Pena, M.J., Peters, D.J.M., Salih, M., Soonawala, D., Spithoven, E.M., Wetzels, J.F., Zietse, R., Gansevoort, R.T., DIPAK-1 Investigators

Publikováno v: Jama : Journal of the American Medical Association, 320, 19, pp. 2010-2019
JAMA-Journal of the American Medical Association, 320(19), 2010-2019. American Medical Association
Journal of the American Medical Association, 320(19), 2010-2019
JAMA, 320(19), 2010-2019. AMER MEDICAL ASSOC
Journal of the American Medical Association
Jama : Journal of the American Medical Association, 320, 2010-2019

Importance: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy. There are limited therapeutic man

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f061ec257f7cd41ff27a101a5407f98
https://doi.org/10.1001/jama.2018.15870